NASDAQ: TTRXTurn Therapeutics Inc Stock
$3.50+0.23 (+7.03%)
Updated Nov 24, 2025
TTRX Price
$3.50
Fair Value Price
N/A
Market Cap
$103.06M
52 Week Low
$2.57
52 Week High
$26.50
P/E
N/A
P/B
204.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
7.53
Operating Cash Flow
N/A
Beta
3.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TTRX Overview
Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TTRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TTRX
Ranked#124 of 485
Ranked#124 of 485
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.78 | A | |
| $332.71 | A | |
| $16.11 | A |
Be the first to know about important TTRX news, forecast changes, insider trades & much more!
TTRX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TTRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TTRX is poor value based on its book value relative to its share price (204.47x), compared to the US Biotechnology industry average (5.15x)
P/B vs Industry Valuation
TTRX's short-term assets ($3.29M) exceed its short-term liabilities ($2.31M)
Short-term Liabilities Financials
TTRX's short-term assets ($3.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more TTRX due diligence checks available for Premium users.
Valuation
TTRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
204.47x
Industry
5.15x
TTRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TTRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
Assets to liabilities
Assets
$4.3M
Liabilities
$3.8M
Debt to equity
7.53
TTRX's short-term assets ($3.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TTRX's short-term assets ($3.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TTRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$588.6k
Investing
-$89.8k
Financing
$594.6k
TTRX vs Biotech Stocks
Turn Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.